Skip to main content
SpringerLink
Log in

Diabetic Kidney Disease

  • Chapter
Cardiorenal Syndrome

  • 1107 Accesses

Abstract

Diabetic nephropathy (DN) is the leading cause of chronic kidney disease and end-stage renal disease (ESRD). Patients with diabetic nephropathy have a high burden of cardiovascular morbidity and mortality. Therefore, interventions that reduce the incidence and progression rate of DN will reduce morbidity and mortality rates as well as health care costs. Hyperglycemia and arterial hypertension are the two main risk factors for DN, but even in the presence of hyperglycemia and elevated blood pressure (BP) for long periods, DN develops only in susceptible patients. Family studies have confirmed the presence of hereditary factors in the development of DN. Besides these four key factors, others have also been implicated, although their impact is less relevant. A systematic approach aiming at prompt diagnosis and intervention can reduce the incidence of DN and slow progression toward ESRD

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ritz E, Koleganova N (2009) Obesity and chronic kidney disease. Semin Nephrol 29:504–511

    Article  PubMed  Google Scholar 

  2. Perkins BA, Ficociello LH, Silva KH et al (2003) Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348:2285–2293

    Article  CAS  PubMed  Google Scholar 

  3. Kramer CK, Leitao CB, Pinto LC et al (2007) Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care 30:1998–2000

    Article  CAS  PubMed  Google Scholar 

  4. Mauer M, Fioretto P, Woredekal Y (2001) Diabetic nephropathy. In: Schrier RW (ed) Disease of the kidney and urinary tract. Philadelphia, Lippincott Williams and Wilkins, pp 2083–2127

    Google Scholar 

  5. Wolf G (2004) New insights into the pathophysiology of diabetic nephropathy: from hemodynamics to molecular pathology. Eur J Clin Invest 34:785–796

    Article  CAS  PubMed  Google Scholar 

  6. Jandeleit-Dahm K Cooper ME (2006) Hypertension and diabetes: role of renin-angiotensin system. Endocrinol Meab Clin North Am 35:469–490

    Article  CAS  Google Scholar 

  7. Jakus V, Rietbrock N (2004) Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 53:131–142

    CAS  PubMed  Google Scholar 

  8. Perkins BA, Nelson RG, Ostrander BE et al (2005) Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 16:1404–1412

    Article  PubMed  Google Scholar 

  9. Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 329:977–986

    Article  Google Scholar 

  10. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352:837–853

    Article  Google Scholar 

  11. The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572

    Article  Google Scholar 

  12. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653

    Article  Google Scholar 

  13. Holman RR, Paul SK, Bethel MA et al (2008) 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589

    Article  CAS  PubMed  Google Scholar 

  14. Parving HH, Lehnert H, Brochner-Mortensen J et al (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New Engl J Med 345:870–878

    Article  CAS  PubMed  Google Scholar 

  15. Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 345: 861–869

    Article  CAS  PubMed  Google Scholar 

  16. Lurbe E, Redon J, Kesani A et al (2002) Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 347:797–805

    Article  CAS  PubMed  Google Scholar 

  17. de la Sierra A, Redon J, Banegas JR et al (2009) Spanish Society of Hypertension Ambulatory Blood Pressure Monitoring Registry Investigators. Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension 53:466–472

    Article  PubMed  Google Scholar 

  18. Ewens KG, George RA, Sharma K et al (2005) Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test. Diabetes 54:3305–3318

    Article  CAS  PubMed  Google Scholar 

  19. Vionnet N, Tregouet D, Kazeem G (2006) Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: strongest evidence for association with a variant in the promoter region of the adiponectin gene. Diabetes 55:3166–3174

    Article  CAS  PubMed  Google Scholar 

  20. Hadjadj S, Tarnow L, Forsblom C (2007) Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. J Am Soc Nephrol 18:1284–1291

    Article  CAS  PubMed  Google Scholar 

  21. Langefeld CD, Beck SR, Bowden DW et al (2004) Heritability of GFR and albuminuria in Caucasians with type 2 diabetes mellitus. Am J Kidney Dis 43:796–800

    Article  PubMed  Google Scholar 

  22. Iyengar SK, Abboud HE, Goddard KA (2007) Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the Family Investigation of Nephropathy and Diabetes (FIND). Diabetes 56:1577–1585

    Article  CAS  PubMed  Google Scholar 

  23. Bowden DW, Colicigno CJ, Langefeld CD (2004) A genome scan for diabetic nephropathy in African Americans. Kidney Int 66:1517–1526

    Article  CAS  PubMed  Google Scholar 

  24. Shimazaki A, Kawamura Y, Kanazawa A (2005) Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes 54:1171–1178

    Article  CAS  PubMed  Google Scholar 

  25. Shimazaki A, Tanaka Y, Shinosaki T et al (2006) ELMO1 increases expression of extracellular matrix proteins and inhibits cell adhesion to ECMs. Kidney Int.70:1769–1776

    Article  CAS  PubMed  Google Scholar 

  26. Brosius FC III (2008) New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord 9:245–254

    Article  CAS  PubMed  Google Scholar 

  27. Ruggenenti P, Perna A, Gherardi G et al (1998) Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 352:1252–1256

    Article  CAS  PubMed  Google Scholar 

  28. Eijkelkamp WB, Zhang Z, Remuzzi G et al (2007) Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 18:1540–1546

    Article  CAS  PubMed  Google Scholar 

  29. Vergouwe Y, Soedamah-Muthu SS, Zgibor J et al (2010) Progression to microalbuminuria in type 1 diabetes: development and validation of a prediction rule. Diabetologia. 53:254–262

    Article  CAS  PubMed  Google Scholar 

  30. Fried LF, Orchard TJ, Kasiske BL for the Lipids and Renal Disease Progression Meta-Analysis Study Group (2001) Effect of lipid reduction on the progression of renal disease: A metaanalysis. Kidney Int 59:260–269

    Article  CAS  PubMed  Google Scholar 

  31. Tonelli M, Collins D, Robins S et al (2004). For the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Investigators. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am J Kidney Dis 44:832–839

    CAS  PubMed  Google Scholar 

  32. FIELD Study Investigators (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 366:1849–1861

    Article  Google Scholar 

  33. Fellstrom B, Holdaas H, Jardine AG et al on behalf of the Assessment of Lescol in Renal Transplantation (ALERT) Study Investigators (2004) Effect of Fluvastatin on Renal Endpoints in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 66:1549–1555

    Article  PubMed  Google Scholar 

  34. Tonelli M, Moye L, Sacks FM et al (2003) For the Cholesterol and Recurrent Events (CARE) Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14:1605–1613

    Article  CAS  PubMed  Google Scholar 

  35. Tonelli M, Isles C, Craven T et al (2005) Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112:171–178

    Article  CAS  PubMed  Google Scholar 

  36. Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360:7–22

    Article  Google Scholar 

  37. Athyros VG, Mikhailidis DP, Papageorgiou AA et al (2004) The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study. J Clin Pathol 57:728–734

    Article  CAS  PubMed  Google Scholar 

  38. Redon J (2005) Urinary albumin excretion: lowering the threshold of risk in hypertension. Hypertension 46:19–20

    Article  CAS  PubMed  Google Scholar 

  39. Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function measured and estimated glomerular filtration rate. N Engl J Med 354:2473–2483

    Article  CAS  PubMed  Google Scholar 

  40. Lurbe E, Cifkova R, Cruickshank JK et al (2009) European Society of Hypertension. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 27:1719–1742

    Article  CAS  PubMed  Google Scholar 

  41. Parati G, Stergiou GS, Asmar R et al (2008) ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 26:1505–1526

    Article  CAS  PubMed  Google Scholar 

  42. Mancia G, De Backer G, Dominiczak A et al (2007) Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology: 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105–1187

    Article  CAS  PubMed  Google Scholar 

  43. Ohkubo Y, Kishikawa H, Araki E et al (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103–117

    Article  CAS  PubMed  Google Scholar 

  44. Duckworth W, Abraira C, Moritz T et al (2009) VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139

    Article  CAS  PubMed  Google Scholar 

  45. Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559

    Article  Google Scholar 

  46. Mancia G, Laurent S, Agabiti-Rosei E et al (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 27:2121–2158

    Article  CAS  PubMed  Google Scholar 

  47. Ravid M, Brosh D, Levi Z et al (1998) Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 128(12 Pt 1):982–988

    CAS  PubMed  Google Scholar 

  48. Bilous R, Chaturvedi N, Sjølie AK et al (2009) Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 151:11–20

    PubMed  Google Scholar 

  49. Mauer M, Zinman B, Gardiner R et al (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361:40–51

    Article  CAS  PubMed  Google Scholar 

  50. Remuzzi G, Macia M, Ruggenenti P (2006) Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol 17(Suppl 2):S90–S97

    Article  PubMed  Google Scholar 

  51. Parving HH, Lehnert H, Brochner-Mortensen J et al (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878

    Article  CAS  PubMed  Google Scholar 

  52. Barnett AH, Bain SC, Bouter P et al (2004) Diabetics Exposed to Telmisartan and Enalapril Study Group: angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952–1961

    Article  CAS  PubMed  Google Scholar 

  53. Casas JP, Chua W, Loukogeorgakis S et al (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026–2033

    Article  CAS  PubMed  Google Scholar 

  54. Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN (2008) Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens 21:922–929

    Article  CAS  PubMed  Google Scholar 

  55. Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30–48

    PubMed  Google Scholar 

  56. Parving HH, Persson F, Lewis JB et al (2008) AVOID study investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:2433–2446

    Article  CAS  PubMed  Google Scholar 

  57. Imai E, Ito S, Haneda M et al, ORIENT investigators (2006) Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design. Hypertens Res. 29:703–709

    Google Scholar 

  58. Parving HH, Brenner BM, McMurray JJ, et al (2009) Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 24:1663–1671

    Article  CAS  PubMed  Google Scholar 

  59. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456–1462

    Article  CAS  PubMed  Google Scholar 

  60. Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine-Hypertension Clinic, Hospital Clinico, University of Valencia, Spain

    Josep Redon

Authors
  1. Josep Redon
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

    Adel E. Berbari

  2. Clinica Medica Department of Clinical Medicine and Prevention, University of Milano-Bicocca San Gerardo Hospital, Monza, Milan, Italy

    Giuseppe Mancia

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Italia

About this chapter

Cite this chapter

Redon, J. (2010). Diabetic Kidney Disease. In: Berbari, A.E., Mancia, G. (eds) Cardiorenal Syndrome. Springer, Milano. https://doi.org/10.1007/978-88-470-1463-3_25

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-1463-3_25

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-1462-6

  • Online ISBN: 978-88-470-1463-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation